Integra LifeSciences (NASDAQ:IART) Trading Up 5.1% – What’s Next?

Integra LifeSciences Holdings Co. (NASDAQ:IART)’s share price was up 5.1% on Monday . The stock traded as high as $22.19 and last traded at $22.21. Approximately 659,940 shares traded hands during trading, an increase of 22% from the average daily volume of 542,139 shares. The stock had previously closed at $21.13.

Analysts Set New Price Targets

IART has been the topic of a number of analyst reports. Morgan Stanley assumed coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price on the stock. Citigroup lifted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Stock Up 4.4 %

The stock’s fifty day simple moving average is $23.71 and its two-hundred day simple moving average is $21.81. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -244.97, a PEG ratio of 0.73 and a beta of 1.17.

Insiders Place Their Bets

In related news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership boosted its stake in Integra LifeSciences by 7.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after buying an additional 913 shares in the last quarter. KBC Group NV grew its stake in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in shares of Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 1,371 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Integra LifeSciences by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company’s stock valued at $872,000 after purchasing an additional 1,437 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its holdings in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after buying an additional 1,931 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.